ReviewJACC. Basic to translational science2016
Mitochondrial Membrane Permeability Inhibitors in Acute Myocardial Infarction: Still Awaiting Translation.
Review in JACC. Basic to translational science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Cardioprotective strategies in myocardial ischemia-reperfusion injury: Implications for improving clinical translation.Journal of molecular and cellular cardiology plus · 2025Review
- CardioprotectionThe Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2024Article
- Clinical and Pharmacological Implications of Time to Treatment with Interleukin-1 Blockade in ST-Segment Elevation Myocardial Infarction.The Journal of pharmacology and experimental therapeutics · 2023Article
- Large animal models of cardiac ischemia-reperfusion injury: Where are we now?Zoological research · 2023Review
- Direct cardiac reprogramming: A new technology for cardiac repair.Journal of molecular and cellular cardiology · 2023Review
- Article
- A possible new activator of PI3K-Huayu Qutan Recipe alleviates mitochondrial apoptosis in obesity rats with acute myocardial infarction.Journal of cellular and molecular medicine · 2022Article
- Soluble RAGE attenuates myocardial I/R injuries via FoxO3-Bnip3 pathway.Cellular and molecular life sciences : CMLS · 2022Article
- Current Status and Limitations of Myocardial Infarction Large Animal Models in Cardiovascular Translational Research.Frontiers in bioengineering and biotechnology · 2021Review
- Ageing, sex, and cardioprotection.British journal of pharmacology · 2020Review
- Mitochondrial dysfunction and oxidative stress in heart disease.Experimental & molecular medicine · 2019Review
- Developing LRP1 Agonists into a Therapeutic Strategy in Acute Myocardial Infarction.International journal of molecular sciences · 2019Review
- Low Density Lipoprotein Receptor-Related Protein-1 in Cardiac Inflammation and Infarct Healing.Frontiers in cardiovascular medicine · 2019Review
- Inflammasome, pyroptosis, and cytokines in myocardial ischemia-reperfusion injury.American journal of physiology. Heart and circulatory physiology · 2018Review
- Low-Density Lipoprotein Receptor-Related Protein-1 Is a Therapeutic Target in Acute Myocardial Infarction.JACC. Basic to translational science · 2017Article
- Association between ROS production, swelling and the respirasome integrity in cardiac mitochondria.Archives of biochemistry and biophysics · 2017Article
- Interleukin-1 Blockade in Acute Myocardial Infarction and Heart Failure: Getting Closer and Closer.JACC. Basic to translational science · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite therapeutic advances, acute myocardial infarction (AMI) remains a leading cause of morbidity and mortality worldwide. One potential limitation of the current treatment paradigm is the lack of effective therapies to optimize reperfusion after ischemia and prevent reperfusion-mediated injury. Experimental studies indicate that this process accounts for up to 50% of the final infarct size, lending it importance as a potential target for cardioprotection. However, multiple therapeutic approaches have shown potential in pre-clinical and early phase trials but a paucity of clear clinical benefit when expanded to larger studies. Here we explore this history of trials and errors of the studies of cyclosporine A and other mitochondrial membrane permeability inhibitors, agents that appeared to have a promising pre-clinical record yet provided disappointing results in phase III clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.